Kristi Carlston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristi Carlston has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Gerald Cochran
Division of Epidemiology, University of Utah, Salt Lake City, UT, USA
3 shared publications Adam J. Gordon
Division of Epidemiology, University of Utah, Salt Lake City, UT, USA
2 shared publications- Adam J. Gordon
Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
2 shared publications Craig Field
Department of Psychology University of Texas, El Paso El Paso Texas USA
2 shared publications- Kenneth Charles Hohmeier
Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, 301 S. Perimeter Park Dr., Suite 220, Nashville, TN 37211, USA
2 shared publications Melissa Tyszko
Division of Epidemiology, University of Utah, Salt Lake City, UT, USA
2 shared publications
Latest Publications
- 18 August 2026
- Published by SAGE Publications in Substance use & addiction journal
Toward a Pharmacy-Led Value-Based Care Model for Buprenorphine Initiation and Management (PharmValue): Development of a Scalable Pharmacist-Led Collaborative Practice Agreement for Medications for Opioid Use Disorder
Opioid use disorder (OUD) treatment needs continue to outpace the capacity of existing treatment systems, with access to buprenorphine particularly constrained in many communities. Pharmacist involvement in medications for OUD (MOUD), including buprenorphine initiation and longitudinal management, has demonstrated feasibility and acceptability in select settings, yet widespread implementation remains limited by regulatory variability and fragmented care models. Pharmacies are highly accessible health care sites, and pharmacists’ scope of practice can be expanded through mechanisms such as collaborative pharmacy practice agreements (CPPAs)—a term used interchangeably in the literature with “collaborative practice agreement” and related variants—to support buprenorphine initiation and ongoing management. The CTN-0151 PharmValue project aims to develop a scalable, pharmacist-led CPPA model for MOUD that can be adapted across diverse state regulatory environments and pharmacy settings. Using a community-engaged research approach and a 50-state legal and regulatory review supplemented by a national expert survey, PharmValue will (1) engage community stakeholders to codevelop a model CPPA and care pathway for pharmacist-managed buprenorphine and (2) identify existing legal authorities and advocacy opportunities to expand pharmacist-managed MOUD care nationally. This protocol commentary describes the rationale, guiding frameworks, and key design decisions underlying the PharmValue model and outlines anticipated implementation challenges and future directions for evaluation and scale-up.
- 18 August 2026
- Published by SAGE Publications in Substance use & addiction journal
Toward a Pharmacy-Led Value-Based Care Model for Buprenorphine Initiation and Management (PharmValue): Development of a Scalable Pharmacist-Led Collaborative Practice Agreement for Medications for Opioid Use Disorder
Opioid use disorder (OUD) treatment needs continue to outpace the capacity of existing treatment systems, with access to buprenorphine particularly constrained in many communities. Pharmacist involvement in medications for OUD (MOUD), including buprenorphine initiation and longitudinal management, has demonstrated feasibility and acceptability in select settings, yet widespread implementation remains limited by regulatory variability and fragmented care models. Pharmacies are highly accessible health care sites, and pharmacists’ scope of practice can be expanded through mechanisms such as collaborative pharmacy practice agreements (CPPAs)—a term used interchangeably in the literature with “collaborative practice agreement” and related variants—to support buprenorphine initiation and ongoing management. The CTN-0151 PharmValue project aims to develop a scalable, pharmacist-led CPPA model for MOUD that can be adapted across diverse state regulatory environments and pharmacy settings. Using a community-engaged research approach and a 50-state legal and regulatory review supplemented by a national expert survey, PharmValue will (1) engage community stakeholders to codevelop a model CPPA and care pathway for pharmacist-managed buprenorphine and (2) identify existing legal authorities and advocacy opportunities to expand pharmacist-managed MOUD care nationally. This protocol commentary describes the rationale, guiding frameworks, and key design decisions underlying the PharmValue model and outlines anticipated implementation challenges and future directions for evaluation and scale-up.
- 10 September 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (10) , 991-1002
Impact of Community Pharmacists on Reducing Opioid and Alcohol Co‐Use: A Pilot Randomized Control Trial of a Medication Therapy Management Intervention
Background: Concurrent use of opioids and alcohol can result in respiratory depression, overdose, and death. Prior research has shown that 20%–30% of patients receiving opioid medications in community pharmacies engage in high‐risk drinking. We adapted a medication therapy management‐based intervention to address co‐use and tested its feasibility, acceptability, and preliminary efficacy.Design: This pilot study enrolled adult, English‐speaking community pharmacy patients dispensed opioids who reported current drinking. Participants were randomized to standard medication counseling (SMC) or alcohol‐targeted brief intervention‐medication therapy management (ABI‐MTM). ABI‐MTM included two pharmacist‐delivered sessions focused on reviewing medications/interactions, motivating participants to discontinue co‐use, and providing a written action plan. We assessed enrollment, retention, intervention delivery, satisfaction, drinks per drinking day (DDD), and daily morphine milligram equivalent (MME) at baseline, 2, and 3 months. Outcomes were analyzed using descriptive statistics and generalized linear mixed modeling.Results: We enrolled 44 patients (110% of target; 22 per group). No significant differences were found in age (mean = 55.8), sex (female = 65.9%), race (White = 95.5%), education (> high school = 95.5%), or health insurance status (insured = 95.5%). Consent and retention rates exceeded 90%, session delivery was ≥ 95%, and ABI‐MTM satisfaction ranged from 79% to 89%. At 3 months, 59.1% of ABI‐MTM participants versus 45.5% of SMC achieved ≥ 30% reduction in DDD and/or daily MME. Mixed models showed ABI‐MTM recipients had 2.10 (95% confidence interval = 0.34–12.95) higher odds of achieving this reduction.Conclusion: ABI‐MTM demonstrated feasibility, acceptability, and preliminary efficacy. A fully powered trial is warranted to evaluate broader implementation.
- 10 September 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (10) , 991-1002
Impact of Community Pharmacists on Reducing Opioid and Alcohol Co‐Use: A Pilot Randomized Control Trial of a Medication Therapy Management Intervention
Background: Concurrent use of opioids and alcohol can result in respiratory depression, overdose, and death. Prior research has shown that 20%–30% of patients receiving opioid medications in community pharmacies engage in high‐risk drinking. We adapted a medication therapy management‐based intervention to address co‐use and tested its feasibility, acceptability, and preliminary efficacy.Design: This pilot study enrolled adult, English‐speaking community pharmacy patients dispensed opioids who reported current drinking. Participants were randomized to standard medication counseling (SMC) or alcohol‐targeted brief intervention‐medication therapy management (ABI‐MTM). ABI‐MTM included two pharmacist‐delivered sessions focused on reviewing medications/interactions, motivating participants to discontinue co‐use, and providing a written action plan. We assessed enrollment, retention, intervention delivery, satisfaction, drinks per drinking day (DDD), and daily morphine milligram equivalent (MME) at baseline, 2, and 3 months. Outcomes were analyzed using descriptive statistics and generalized linear mixed modeling.Results: We enrolled 44 patients (110% of target; 22 per group). No significant differences were found in age (mean = 55.8), sex (female = 65.9%), race (White = 95.5%), education (> high school = 95.5%), or health insurance status (insured = 95.5%). Consent and retention rates exceeded 90%, session delivery was ≥ 95%, and ABI‐MTM satisfaction ranged from 79% to 89%. At 3 months, 59.1% of ABI‐MTM participants versus 45.5% of SMC achieved ≥ 30% reduction in DDD and/or daily MME. Mixed models showed ABI‐MTM recipients had 2.10 (95% confidence interval = 0.34–12.95) higher odds of achieving this reduction.Conclusion: ABI‐MTM demonstrated feasibility, acceptability, and preliminary efficacy. A fully powered trial is warranted to evaluate broader implementation.
- 11 July 2025
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 46 (4) , 1040-1046
Protocol Commentary for the SUCCESS (Successful Recruitment and Retention in a Randomized Controlled Trial of Pregnant Participants with Opioid Use Disorder) Study
Opioid use disorder (OUD) and resulting opioid-related overdoses are significant contributors to maternal morbidity and mortality. Yet very few clinical trials focus on evaluating the efficacy of medications for OUD among pregnant populations. Understanding challenges to the recruitment and retention of pregnant participants with OUD in clinical trials and identifying effective strategies to overcome these barriers are urgently needed to help improve outcomes. The SUCCESSful recruitment and retention in a randomized controlled trial of pregnant participants with opioid use disorder (SUCCESS) study was conceptualized and designed by researchers from the Medication treatment for Opioid use disorder in expectant Mothers (MOMs) trial (NIH NIDA NCT03918850). The objective of the SUCCESS study is to identify strategies, facilitators, and barriers to recruiting and retaining pregnant and postpartum participants with OUD in the MOMs trial. The SUCCESS study entails (1) semi-structured interviews with researchers from all 13 MOMs sites, (2) focus groups with MOMs trial participants, and (3) a modified Delphi process to develop data-driven guidance for future clinical trials. This commentary describes the motivation to conduct this study, presents our conceptual framework and critical decision points in protocol development, and describes the proposed product of this study.
- 11 July 2025
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 46 (4) , 1040-1046
Protocol Commentary for the SUCCESS (Successful Recruitment and Retention in a Randomized Controlled Trial of Pregnant Participants with Opioid Use Disorder) Study
Opioid use disorder (OUD) and resulting opioid-related overdoses are significant contributors to maternal morbidity and mortality. Yet very few clinical trials focus on evaluating the efficacy of medications for OUD among pregnant populations. Understanding challenges to the recruitment and retention of pregnant participants with OUD in clinical trials and identifying effective strategies to overcome these barriers are urgently needed to help improve outcomes. The SUCCESSful recruitment and retention in a randomized controlled trial of pregnant participants with opioid use disorder (SUCCESS) study was conceptualized and designed by researchers from the Medication treatment for Opioid use disorder in expectant Mothers (MOMs) trial (NIH NIDA NCT03918850). The objective of the SUCCESS study is to identify strategies, facilitators, and barriers to recruiting and retaining pregnant and postpartum participants with OUD in the MOMs trial. The SUCCESS study entails (1) semi-structured interviews with researchers from all 13 MOMs sites, (2) focus groups with MOMs trial participants, and (3) a modified Delphi process to develop data-driven guidance for future clinical trials. This commentary describes the motivation to conduct this study, presents our conceptual framework and critical decision points in protocol development, and describes the proposed product of this study.
- 1 July 2023
- Published by SAGE Publications in Substance Abuse
- Vol. 44 (3) , 130-135
Co-use of Opioid Medications and Alcohol Prevention Study (COAPS)
While there is limited research in the field regarding the various dimensions of co-use of alcohol and opioid medication, particularly related to co-use and levels of severity, our research has shown 20% to 30% of community pharmacy patients receiving opioid pain medications are engaged in co-use. Co-use of alcohol and opioid medications is a significant risk factor for opioid-related overdose. Community pharmacy is a valuable yet underutilized resource and setting for addressing the US opioid epidemic, with an untapped potential for identification of and intervention for risks associated with co-use of alcohol and opioids. This commentary describing the “Co-use of Opioid Medications and Alcohol Prevention Study (COAPS)” offers an innovative and promising approach to mitigating serious risks associated with co-use of alcohol (risk and non-risk use) and opioids in community pharmacy. COAPS aim 1involves adapting an existing opioid misuse intervention to target co-use of alcohol and opioid mediations. COAPS aim 2 involves testing the adapted intervention within a small-scale pilot randomized controlled trial (N = 40) to examine feasibility, acceptability and preliminary efficacy of the intervention versus standard care. COAPS aim 3 involves conducting key informant interviews related to future implementation of larger scale studies or service delivery in community pharmacy settings.
- 1 July 2023
- Published by SAGE Publications in Substance Abuse
- Vol. 44 (3) , 130-135
Co-use of Opioid Medications and Alcohol Prevention Study (COAPS)
While there is limited research in the field regarding the various dimensions of co-use of alcohol and opioid medication, particularly related to co-use and levels of severity, our research has shown 20% to 30% of community pharmacy patients receiving opioid pain medications are engaged in co-use. Co-use of alcohol and opioid medications is a significant risk factor for opioid-related overdose. Community pharmacy is a valuable yet underutilized resource and setting for addressing the US opioid epidemic, with an untapped potential for identification of and intervention for risks associated with co-use of alcohol and opioids. This commentary describing the “Co-use of Opioid Medications and Alcohol Prevention Study (COAPS)” offers an innovative and promising approach to mitigating serious risks associated with co-use of alcohol (risk and non-risk use) and opioids in community pharmacy. COAPS aim 1involves adapting an existing opioid misuse intervention to target co-use of alcohol and opioid mediations. COAPS aim 2 involves testing the adapted intervention within a small-scale pilot randomized controlled trial (N = 40) to examine feasibility, acceptability and preliminary efficacy of the intervention versus standard care. COAPS aim 3 involves conducting key informant interviews related to future implementation of larger scale studies or service delivery in community pharmacy settings.